A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells.

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells.
复制标题

一种靶向 gp120 和 gp41 的毒素缀合重组蛋白,用于灭活 HIV-1 病毒粒子并杀死潜伏期逆转剂重新激活的潜伏细胞。

DOI:
10.1128/mbio.03384-21
复制
发表时间:
2022-02-22
期刊:
影响因子:
6.4
通讯作者:
Jiang S
Jiang S
中科院分区:
生物学1区
文献类型:
--
作者:
Wang X;Xu W;Liu Z;Wu Y;Wang Q;Cao M;Ying T;He N;Lu L;Jiang S

文献摘要

参考文献

相似文献

抗逆转录病毒联合疗法(cART)的应用已将艾滋病降低为一种可控制的慢性传染病。然而,由于潜伏库的存在,HIV/AIDS无法治愈,因此需要开发能够消除潜伏逆转剂(LRA)激活的HIV-1病毒粒子和潜伏细胞的抗逆转录病毒药物。在这项研究中,我们将一种小分子毒素DM1偶联到gp120结合蛋白mD1.22(一种突变的CD4结构域I)上,发现mD1.22-DM1可以灭活HIV-1病毒粒子。然而,它不能杀死lra激活的潜伏细胞。然后,我们设计并构建了一个双靶向蛋白DL35D,通过连接mD1.22和gp41 nr特异性抗体D5的单链可变片段(scFv),用一个35-mer的连接体。随后,我们将DM1偶联到DL35D上,发现DL35D-DM1可以抑制HIV-1感染,灭活HIV-1病毒粒子,杀死HIV-1感染细胞和lra再激活的潜伏细胞,这表明这种毒素偶联的双靶向重组蛋白是一种有希望进一步开发的新型抗病毒药物,具有潜在的HIV功能性治愈潜力。
Application of the combination antiretroviral therapy (cART) has reduced AIDS to a manageable chronic infectious disease. However, HIV/AIDS cannot be cured because of the presence of latent reservoirs, thus calling for the development of antiretroviral drugs that can eliminate latency-reversing agent (LRA)-activated HIV-1 virions and latent cells. In this study, we conjugated a small-molecule toxin, DM1, to a gp120-binding protein, mD1.22, a mutated CD4 domain I, and found that mD1.22-DM1 could inactivate HIV-1 virions. However, it could not kill LRA-activated latent cells. We then designed and constructed a dual-targeting protein, DL35D, by linking mD1.22 and the single-chain variable fragment (scFv) of a gp41 NHR-specific antibody, D5, with a 35-mer linker. Subsequently, we conjugated DM1 to DL35D and found that DL35D-DM1 could inhibit HIV-1 infection, inactivate HIV-1 virions, kill HIV-1-infected cells and LRA-reactivated latent cells, suggesting that this toxin-conjugated dual-targeting recombinant protein is a promising candidate for further development as a novel antiviral drug with potential for HIV functional cure.
DOI: 10.1371/journal.pone.0239813
发表时间: 2020
期刊: PloS one
影响因子: 3.7
作者:
Chiang ZC;Chiu YK;Lee CC;Hsu NS;Tsou YL;Chen HS;Hsu HR;Yang TJ;Yang AS;Wang AH
通讯作者: Wang AH
DOI: 10.1016/j.addr.2012.09.039
发表时间: 2013-10
影响因子: 16.1
作者:
Chen, Xiaoying;Zaro, Jennica L.;Shen, Wei-Chiang
通讯作者: Shen, Wei-Chiang
DOI: 10.1158/0008-5472.can-05-4489
发表时间: 2006-04-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Erickson, HK;Park, PU;Blättler, WA
通讯作者: Blättler, WA
DOI: 10.1126/science.6189183
发表时间: 1983-01-01
期刊: SCIENCE
影响因子: 56.9
作者:
BARRESINOUSSI, F;CHERMANN, JC;MONTAGNIER, L
通讯作者: MONTAGNIER, L
DOI: 10.1128/jvi.02566-13
发表时间: 2014-01-01
影响因子: 5.4
作者:
Chen, Weizao;Feng, Yang;Dimitrov, Dimiter S.
通讯作者: Dimitrov, Dimiter S.